Much of the recent excitement in the translational field of tumor immunology and
immunotherapy has been generated by the recognition that immune checkpoint proteins can …

Lysophosphatidic acid (LPA) is a potent bioactive phospholipid that stimulates a variety of
cellular responses by acting on cognate G protein-coupled receptors (GPCRs). There is …

Combination therapy with α-CTLA-4 and α-PD-1 has shown significant clinical responses in
different types of cancer. However, the underlying mechanisms remain elusive. Here …

The programmed death-ligand 1 (PD-L1), by binding to PD-1 on the surface of immune cells,
activates a major immune checkpoint pathway. Elevated expression of PD-L1 in tumor cells …

Lysophosphatidic acid (LPA) can affect the growth, migration, and activation of many
different cell types. Research in this field has recently accelerated due to the molecular …

The programmed cell death protein-1 (PD-1) is highly expressed on the surface of antigen-
specific exhausted T cells and, upon interaction with its ligand PD-L1, can result in inhibition …

The recent success of PD-1 and PD-L1 blockade in cancer therapy illustrates the important
role of the PD-1/PD-L1 pathway in the regulation of antitumor immune responses. However …

Background Immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and
the programmed cell death protein-1/programmed death-ligand 1 (PD-1/PD-L1) have …

Although cancer immunotherapy based on immune checkpoint blockade has shown
promising clinical responses, the limited host response rate and systemic side effects still …

ABSTRACT PT-112 is a novel platinum-pyrophosphate conjugate under clinical
development for cancer therapy. PT-112 mediates cytostatic and cytotoxic effects against a …